About this Research Topic
Seizures in Alzheimer’s disease (AD) deserve increased attention because they have a harmful impact on patients, can easily go undetected and untreated, and may contribute to disease progression. Up to 60% of patients with Alzheimer’s disease (AD) develop seizures and subclinical epileptiform activity, and such network hyperactivity may lead to faster cognitive decline. Emerging evidence from transgenic animal models of AD suggest that anti-seizure therapies may improve cognition in the disease. Clinical trials are underway to determine if certain antiseizure drugs (ASDs) can improve symptoms and slow progression in AD. The clinical management of seizures associated with AD is evolving with advances in neurophysiological monitoring and therapies.
The goal of this Research Topic is to build on concepts for mechanisms and novel treatments for network hyperexcitability in AD. Articles covering network hyperexcitability in AD, spanning animal models and human disease will be welcomed. Articles should address basic science concepts and novel therapies for network hyperexcitability in Alzheimer’s disease and related disorders. Basic science articles should discuss mechanisms underlying epileptogenesis in AD, as well as novel therapies ranging from pharmacological, gene targeting, and stem cell approaches. Clinical articles should discuss advances in the workup and management of seizures, and other forms of network hyperexcitability, in mild cognitive impairment and AD. Topics may include the observed relationship between seizures and sleep in AD. Illustrative case descriptions are encouraged.
Keywords: Seizures, Epileptic Activity, Alzheimer’s disease, Mild Cognitive Impairment, Memory Loss
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.